Liquidia Reports Q4 Earnings with Revenue Beat
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy LQDA?
Source: seekingalpha
- Earnings Performance: Liquidia reported a Q4 GAAP EPS of $0.15, missing expectations by $0.05, indicating potential pressure on profitability that may affect investor confidence.
- Revenue Surge: The company achieved Q4 revenue of $92.02 million, reflecting a staggering 3051.4% year-over-year increase, surpassing market expectations by $4.53 million, demonstrating strong product demand and ongoing market share expansion.
- Market Outlook: Liquidia is poised for robust performance in the coming years, particularly with a strong outlook for 2026, highlighting its competitive advantages in specific markets.
- Industry Dynamics: Despite Liquidia's stock facing pressure due to United Therapeutics considering a new treprostinil formulation, the company is actively pursuing special situation gains and long-term growth opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LQDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LQDA
Wall Street analysts forecast LQDA stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 31.780
Low
31.00
Averages
47.50
High
67.00
Current: 31.780
Low
31.00
Averages
47.50
High
67.00
About LQDA
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Liquidia Set to Announce FY Earnings on March 5
- Earnings Announcement: Liquidia (LQDA) is set to announce its FY earnings on March 5 before market open, with a consensus EPS estimate of -$0.62, reflecting a 62.7% year-over-year improvement, indicating potential for enhanced profitability.
- Revenue Surge Expected: The revenue estimate stands at $153.82 million, representing a staggering 999.5% year-over-year increase, which highlights significant growth in market share and product sales, likely boosting investor confidence moving forward.
- Performance Review: Over the past year, Liquidia has not met EPS estimates at all, while it has only met revenue estimates 25% of the time, suggesting a need for improvement in profitability despite a relatively strong revenue performance.
- Estimate Revision Trends: In the last three months, EPS estimates have seen two upward and two downward revisions, while revenue estimates experienced four upward and two downward revisions, indicating analyst divergence and uncertainty regarding Liquidia's future performance.
See More
Liquidia Reports Strong Q4 Results with YUTREPIA Traction
- Financial Highlights: Liquidia reported Q4 revenue of $92.02 million, exceeding analysts' expectations of $83.70 million, although its earnings per share (EPS) of $0.15 fell short of the $0.19 estimate, indicating strong revenue growth despite EPS challenges.
- Product Revenue Surge: The revenue from YUTREPIA is projected to reach approximately $148.3 million in 2025, with about $90.1 million generated in Q4 alone, showcasing significant early traction in the drug's commercial rollout.
- Positive Market Reaction: Following the earnings report, Liquidia's stock traded over 6% higher in Thursday's premarket, reflecting investor optimism regarding the company's growth potential.
- Strategic Implications: While EPS did not meet expectations, the robust revenue growth and favorable market response suggest that Liquidia is on a promising path in the commercialization of its respiratory drug, potentially laying the groundwork for sustained future growth.
See More
Liquidia Reports Q4 Earnings with Revenue Beat
- Earnings Performance: Liquidia reported a Q4 GAAP EPS of $0.15, missing expectations by $0.05, indicating potential pressure on profitability that may affect investor confidence.
- Revenue Surge: The company achieved Q4 revenue of $92.02 million, reflecting a staggering 3051.4% year-over-year increase, surpassing market expectations by $4.53 million, demonstrating strong product demand and ongoing market share expansion.
- Market Outlook: Liquidia is poised for robust performance in the coming years, particularly with a strong outlook for 2026, highlighting its competitive advantages in specific markets.
- Industry Dynamics: Despite Liquidia's stock facing pressure due to United Therapeutics considering a new treprostinil formulation, the company is actively pursuing special situation gains and long-term growth opportunities.
See More
Liquidia Reports Strong 2025 Financial Performance with YUTREPIA Sales
- Sales Growth: In 2025, YUTREPIA® achieved net product sales of $148.3 million, with fourth-quarter sales reaching $90.1 million, indicating strong market demand and product acceptance, thereby solidifying Liquidia's position in the specialty drug market.
- Profitability Improvement: The company recorded a net income of $14.6 million in the fourth quarter of 2025, marking its second consecutive profitable quarter, demonstrating rapid financial stability post-launch and enhancing its capacity for future investments and expansions.
- Strong Cash Position: As of December 31, 2025, Liquidia's cash and cash equivalents totaled $190.7 million, an increase of $33.2 million from the third quarter, ensuring financial flexibility for future R&D and marketing initiatives.
- Prescription Growth: Since its launch in June 2025, YUTREPIA has received over 3,600 unique prescriptions and treated more than 2,900 patients, with a prescription-to-start conversion rate maintained above 85%, reflecting high recognition and trust from both physicians and patients.
See More
Opaleye Management Sells Liquidia Shares Worth $5.12 Million
- Share Sale Details: Opaleye Management disclosed in an SEC filing on February 17, 2026, that it sold 180,000 shares of Liquidia, valued at approximately $5.12 million, indicating a strategic reduction in its holdings.
- Holding Proportion Change: Following this transaction, Opaleye's stake in Liquidia decreased to 2.435 million shares, representing 11.21% of its reportable AUM, reflecting a cautious outlook on the company's future performance.
- Market Performance Analysis: As of February 17, 2026, Liquidia's stock was priced at $33.84, marking a 105.7% increase over the past year, significantly outperforming the S&P 500 by 97 percentage points, showcasing its strong growth potential in the biopharmaceutical sector.
- Company Overview: Liquidia focuses on innovative therapies for pulmonary arterial hypertension, primarily generating revenue through the development and commercialization of proprietary and generic therapies, demonstrating its competitive advantage in a highly regulated pharmaceutical industry.
See More
Liquidia Corp and MP Materials See Surge in Options Trading Volume
- Liquidia Options Activity: Liquidia Corp (LQDA) saw options trading volume of 10,829 contracts, equating to approximately 1.1 million shares, or about 55.9% of its average daily trading volume of 1.9 million shares over the past month, indicating heightened market interest.
- High Volume Insights: Notably, the $40 strike call option expiring January 23, 2026, recorded 1,601 contracts traded today, representing around 160,100 underlying shares of LQDA, suggesting bullish sentiment among investors regarding its price trajectory.
- MP Materials Options Surge: MP Materials Corp (MP) experienced options trading volume of 43,698 contracts, translating to about 4.4 million shares, or approximately 55.5% of its average daily trading volume of 7.9 million shares in the past month, reflecting strong investor engagement.
- Put Option Trading: The $65 strike put option expiring January 23, 2026, saw 2,986 contracts traded today, representing approximately 298,600 underlying shares of MP, indicating market concerns over potential downside risks in its stock price.
See More
Liquidia Set to Announce FY Earnings on March 5
- Earnings Announcement: Liquidia (LQDA) is set to announce its FY earnings on March 5 before market open, with a consensus EPS estimate of -$0.62, reflecting a 62.7% year-over-year improvement, indicating potential for enhanced profitability.
- Revenue Surge Expected: The revenue estimate stands at $153.82 million, representing a staggering 999.5% year-over-year increase, which highlights significant growth in market share and product sales, likely boosting investor confidence moving forward.
- Performance Review: Over the past year, Liquidia has not met EPS estimates at all, while it has only met revenue estimates 25% of the time, suggesting a need for improvement in profitability despite a relatively strong revenue performance.
- Estimate Revision Trends: In the last three months, EPS estimates have seen two upward and two downward revisions, while revenue estimates experienced four upward and two downward revisions, indicating analyst divergence and uncertainty regarding Liquidia's future performance.
See More
Liquidia Reports Strong Q4 Results with YUTREPIA Traction
- Financial Highlights: Liquidia reported Q4 revenue of $92.02 million, exceeding analysts' expectations of $83.70 million, although its earnings per share (EPS) of $0.15 fell short of the $0.19 estimate, indicating strong revenue growth despite EPS challenges.
- Product Revenue Surge: The revenue from YUTREPIA is projected to reach approximately $148.3 million in 2025, with about $90.1 million generated in Q4 alone, showcasing significant early traction in the drug's commercial rollout.
- Positive Market Reaction: Following the earnings report, Liquidia's stock traded over 6% higher in Thursday's premarket, reflecting investor optimism regarding the company's growth potential.
- Strategic Implications: While EPS did not meet expectations, the robust revenue growth and favorable market response suggest that Liquidia is on a promising path in the commercialization of its respiratory drug, potentially laying the groundwork for sustained future growth.
See More
Liquidia Reports Q4 Earnings with Revenue Beat
- Earnings Performance: Liquidia reported a Q4 GAAP EPS of $0.15, missing expectations by $0.05, indicating potential pressure on profitability that may affect investor confidence.
- Revenue Surge: The company achieved Q4 revenue of $92.02 million, reflecting a staggering 3051.4% year-over-year increase, surpassing market expectations by $4.53 million, demonstrating strong product demand and ongoing market share expansion.
- Market Outlook: Liquidia is poised for robust performance in the coming years, particularly with a strong outlook for 2026, highlighting its competitive advantages in specific markets.
- Industry Dynamics: Despite Liquidia's stock facing pressure due to United Therapeutics considering a new treprostinil formulation, the company is actively pursuing special situation gains and long-term growth opportunities.
See More
Liquidia Reports Strong 2025 Financial Performance with YUTREPIA Sales
- Sales Growth: In 2025, YUTREPIA® achieved net product sales of $148.3 million, with fourth-quarter sales reaching $90.1 million, indicating strong market demand and product acceptance, thereby solidifying Liquidia's position in the specialty drug market.
- Profitability Improvement: The company recorded a net income of $14.6 million in the fourth quarter of 2025, marking its second consecutive profitable quarter, demonstrating rapid financial stability post-launch and enhancing its capacity for future investments and expansions.
- Strong Cash Position: As of December 31, 2025, Liquidia's cash and cash equivalents totaled $190.7 million, an increase of $33.2 million from the third quarter, ensuring financial flexibility for future R&D and marketing initiatives.
- Prescription Growth: Since its launch in June 2025, YUTREPIA has received over 3,600 unique prescriptions and treated more than 2,900 patients, with a prescription-to-start conversion rate maintained above 85%, reflecting high recognition and trust from both physicians and patients.
See More
Opaleye Management Sells Liquidia Shares Worth $5.12 Million
- Share Sale Details: Opaleye Management disclosed in an SEC filing on February 17, 2026, that it sold 180,000 shares of Liquidia, valued at approximately $5.12 million, indicating a strategic reduction in its holdings.
- Holding Proportion Change: Following this transaction, Opaleye's stake in Liquidia decreased to 2.435 million shares, representing 11.21% of its reportable AUM, reflecting a cautious outlook on the company's future performance.
- Market Performance Analysis: As of February 17, 2026, Liquidia's stock was priced at $33.84, marking a 105.7% increase over the past year, significantly outperforming the S&P 500 by 97 percentage points, showcasing its strong growth potential in the biopharmaceutical sector.
- Company Overview: Liquidia focuses on innovative therapies for pulmonary arterial hypertension, primarily generating revenue through the development and commercialization of proprietary and generic therapies, demonstrating its competitive advantage in a highly regulated pharmaceutical industry.
See More
Liquidia Corp and MP Materials See Surge in Options Trading Volume
- Liquidia Options Activity: Liquidia Corp (LQDA) saw options trading volume of 10,829 contracts, equating to approximately 1.1 million shares, or about 55.9% of its average daily trading volume of 1.9 million shares over the past month, indicating heightened market interest.
- High Volume Insights: Notably, the $40 strike call option expiring January 23, 2026, recorded 1,601 contracts traded today, representing around 160,100 underlying shares of LQDA, suggesting bullish sentiment among investors regarding its price trajectory.
- MP Materials Options Surge: MP Materials Corp (MP) experienced options trading volume of 43,698 contracts, translating to about 4.4 million shares, or approximately 55.5% of its average daily trading volume of 7.9 million shares in the past month, reflecting strong investor engagement.
- Put Option Trading: The $65 strike put option expiring January 23, 2026, saw 2,986 contracts traded today, representing approximately 298,600 underlying shares of MP, indicating market concerns over potential downside risks in its stock price.
See More
